Plague Vaccine
DynPort Vaccine begins phase II trial for plague vaccine candidate
Published in Vaccine Weekly, August 9th, 2006
The phase 2 trial will test different vaccine dosages and schedules in 400 healthy volunteers between the ages of 18 and 55. The clinical trial is underway and will continue into 2007 at eight locations across the United States.
"An effective, licensed plague vaccine is a crucial component of U.S. biodefense initiatives," said Robert V. House, president and chief scientific officer of DVC. "Plague has been identified as a Category A bioterrorism agent by the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2006-08-09)
More Articles from Vaccine Weekly
- Breast Cancer Vaccine
CIITA-induced MHC class II expression leads to breast tumor rejection - Cancer Vaccine
Dendritic cell vaccine induces T cell response against tongue squamous carcinoma - Contraception
Sperm DNA vaccine has contraceptive effects in female mice - Pancreatic Cancer
Connective tissue growth factor-specific monoclonal antibodies inhibit pancreatic tumors - Vaccine Efficacy
IL-2 signals during priming are required for expansion of CD8+ memory T cells - Adrenocortical Cancer
Adrenocortical carcinoma management depends on better understanding of molecular pathogenesis - More from this issue of Vaccine Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
